Free tool
FAERS Monitor: Tyzavan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211962 or its brand name (Tyzavan, Vancomycin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
58,342
Serious
53,932
92% of reports
Hospitalization
31,693
Death reported
11,489
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective6,607
- acute kidney injury4,422
- off label use4,327
- pyrexia3,646
- drug reaction with eosinophilia and systemic symptoms2,411
- renal failure2,243
- diarrhoea2,123
- sepsis2,115
- condition aggravated1,970
- pneumonia1,959
- hypotension1,948
- rash1,882
- dyspnoea1,652
- septic shock1,639
- nausea1,592
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 798 |
| 2005 | 863 |
| 2006 | 930 |
| 2007 | 720 |
| 2008 | 847 |
| 2009 | 931 |
| 2010 | 1,241 |
| 2011 | 1,805 |
| 2012 | 1,749 |
| 2013 | 1,667 |
| 2014 | 1,787 |
| 2015 | 2,199 |
| 2016 | 2,602 |
| 2017 | 3,174 |
| 2018 | 4,303 |
| 2019 | 4,023 |
| 2020 | 4,815 |
| 2021 | 4,489 |
| 2022 | 3,937 |
| 2023 | 4,011 |
| 2024 | 4,398 |
| 2025 | 4,351 |
| 2026 | 2,698 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,995,817 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug reaction with eosinophilia and systemic symptomsSignal | 2,411 | 37.2 | 35.7 | 76,967 |
| septic shockSignal | 1,639 | 14.1 | 13.4 | 19,183 |
| acute kidney injurySignal | 4,422 | 10.7 | 10.4 | 38,017 |
| sepsisSignal | 2,115 | 6.9 | 6.7 | 10,617 |
| renal failureSignal | 2,243 | 6.2 | 5.9 | 9,623 |
| pyrexiaSignal | 3,646 | 3.8 | 3.7 | 7,662 |
| hypotensionSignal | 1,948 | 3.5 | 3.4 | 3,521 |
| condition aggravatedSignal | 1,970 | 2.3 | 2.2 | 1,530 |
| pneumoniaSignal | 1,959 | 2.2 | 2.1 | 1,275 |
| drug ineffective | 6,607 | 1.8 | 1.8 | 2,548 |
| off label use | 4,327 | 1.8 | 1.7 | 1,551 |
| rash | 1,882 | 1.6 | 1.5 | 383 |
| diarrhoea | 2,123 | 1.2 | 1.1 | 64 |
| dyspnoea | 1,652 | 1.1 | 1.0 | 4 |
| nausea | 1,592 | 0.7 | 0.7 | 173 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.